

Crmen Brs-Silva

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7912187/carmen-bras-silva-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

39
papers

743
citations

15
h-index

26
g-index

53
ext. papers

901
ext. citations

5.7
avg, IF

3.84
L-index

#	Paper	IF	Citations
39	Heart Failure with Preserved Ejection Fraction: a Pharmacotherapeutic Update.. <i>Cardiovascular Drugs and Therapy</i> , 2022 , 1	3.9	1
38	Urocortins as biomarkers in cardiovascular disease.. <i>Clinical Science</i> , 2022 , 136, 1-14	6.5	
37	Urocortin-2 in Acute Heart Failure: Role as a Marker of Volume Overload and Pulmonary Hypertension. <i>Current Problems in Cardiology</i> , 2021 , 47, 100860	17.1	1
36	Kcnk3 dysfunction exaggerates the development of pulmonary hypertension induced by left ventricular pressure overload. <i>Cardiovascular Research</i> , 2021 , 117, 2474-2488	9.9	4
35	Persistent Pulmonary Hypertension of the Newborn: Pathophysiological Mechanisms and Novel Therapeutic Approaches. <i>Frontiers in Pediatrics</i> , 2020 , 8, 342	3.4	12
34	Efficacy of the thromboxane receptor antagonist NTP42 alone, or in combination with sildenafil, in the sugen/hypoxia-induced model of pulmonary arterial hypertension. <i>European Journal of Pharmacology</i> , 2020 , 889, 173658	5.3	3
33	Cardiovascular Effects of Urocortin-2: Pathophysiological Mechanisms and Therapeutic Potential. <i>Cardiovascular Drugs and Therapy</i> , 2019 , 33, 599-613	3.9	6
32	Novel insights into the role of urotensin II in cardiovascular disease. <i>Drug Discovery Today</i> , 2019 , 24, 2170-2180	8.2	1806
31	Neuregulin-1 attenuates right ventricular diastolic stiffness in experimental pulmonary hypertension. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2019 , 46, 255-265	3	4
30	Bmpr2 Mutant Rats Develop Pulmonary and Cardiac Characteristics of Pulmonary Arterial Hypertension. <i>Circulation</i> , 2019 , 139, 932-948	16.7	50
29	Update on pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2019 , 46, 204-215	3	21
28	Loss of KCNK3 is a hallmark of RV hypertrophy/dysfunction associated with pulmonary hypertension. <i>Cardiovascular Research</i> , 2018 , 114, 880-893	9.9	31
27	Urocortin-2 improves right ventricular function and attenuates pulmonary arterial hypertension. <i>Cardiovascular Research</i> , 2018 , 114, 1165-1177	9.9	12
26	Improvement in left intraventricular pressure gradients after aortic valve replacement in aortic stenosis patients. <i>Experimental Physiology</i> , 2017 , 102, 411-421	2.4	3
25	Neuregulin-1 improves right ventricular function and attenuates experimental pulmonary arterial hypertension. <i>Cardiovascular Research</i> , 2016 , 109, 44-54	9.9	22
24	Distinct right ventricle remodeling in response to pressure overload in the rat. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2016 , 311, H85-95	5.2	24
23	Pulmonary arterial hypertension: Basic knowledge for clinicians. <i>Archives of Cardiovascular Diseases</i> , 2016 , 109, 550-561	2.7	25

22	Urocortin 2 in cardiovascular health and disease. <i>Drug Discovery Today</i> , 2015 , 20, 906-14	8.8	19
21	Cardiovascular ageing 2015 , 203-245		
20	P505Neuregulin-1 ameliorates right ventricular diastolic dysfunction in pulmonary arterial hypertension. <i>Cardiovascular Research</i> , 2014 , 103, S92.4-S92	9.9	
19	P755Molecular mechanisms underlying the beneficial effects of neuregulin-1 in pulmonary arterial hypertension. <i>Cardiovascular Research</i> , 2014 , 103, S138.3-S138	9.9	
18	Angiotensin-(1-7) modulates angiotensin II-induced vasoconstriction in human mammary artery. <i>Cardiovascular Drugs and Therapy</i> , 2014 , 28, 513-22	3.9	14
17	Therapeutic potential of neuregulin-1 in cardiovascular disease. <i>Drug Discovery Today</i> , 2013 , 18, 836-42	8.8	40
16	Intraventricular pressure gradients throughout the cardiac cycle: effects of ischaemia and modulation by afterload. <i>Experimental Physiology</i> , 2013 , 98, 149-60	2.4	12
15	Cardiotoxicity associated with cancer therapy: pathophysiology and prevention strategies. <i>Revista Portuguesa De Cardiologia</i> , 2013 , 32, 395-409	1	45
14	Rodent models of heart failure: an updated review. <i>Heart Failure Reviews</i> , 2013 , 18, 219-49	5	50
13	Neuregulin-1 modulates right ventricle cardiomyocyte function in pulmonary arterial hypertension. <i>European Heart Journal</i> , 2013 , 34, P5029-P5029	9.5	
12	Left intraventricular diastolic and systolic pressure gradients. <i>Experimental Biology and Medicine</i> , 2011 , 236, 1364-72	3.7	4
11	A Western-type diet attenuates pulmonary hypertension with heart failure and cardiac cachexia in rats. <i>Journal of Nutrition</i> , 2011 , 141, 1954-60	4.1	15
10	Effects of adrenomedullin on systolic and diastolic myocardial function. <i>Peptides</i> , 2009 , 30, 796-802	3.8	8
9	Myocardial effects of endothelin-1. <i>Revista Portuguesa De Cardiologia</i> , 2008 , 27, 925-51	1	9
8	Urotensin II acutely increases myocardial length and distensibility: potential implications for diastolic function and ventricular remodeling. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2007 , 376, 107-15	3.4	12
7	Cardiovascular endothelins: essential regulators of cardiovascular homeostasis 2006 , 111, 508-31		144
6	M-mode and Doppler echocardiographic reference values for male New Zealand white rabbits. <i>American Journal of Veterinary Research</i> , 2006 , 67, 1725-9	1.1	24
5	Myocardial dysfunction and neurohumoral activation without remodeling in left ventricle of monocrotaline-induced pulmonary hypertensive rats. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2006 , 291, H1587-94	5.2	53

4	Obligatory role of the endocardial endothelium in the increase of myocardial distensibility induced by endothelin-1. <i>Experimental Biology and Medicine</i> , 2006 , 231, 876-81	3-7	3
3	Impaired response to ET(B) receptor stimulation in heart failure: functional evidence of endocardial endothelial dysfunction?. <i>Experimental Biology and Medicine</i> , 2006 , 231, 893-8	3-7	6
2	Inotropic effects of ETB receptor stimulation and their modulation by endocardial endothelium, NO, and prostaglandins. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2004 , 287, H1194-9	5-2	20
1	ET-1 increases distensibility of acutely loaded myocardium: a novel ETA and Na ⁺ /H ⁺ exchanger-mediated effect. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2003 , 284, H1332-9	5-2	21